Squamous cell carcinoma does not turn into melanoma. These two skin cancers arise from entirely different cell types, and one does not transform into the other during the course of disease. Squamous cell carcinoma develops from keratinocytes, the cells that form the outermost protective layer of skin, while melanoma originates from melanocytes, the pigment-producing cells that sit deeper in the skin’s basal layer. That said, the question is understandable: the two cancers can look alike under certain circumstances, occasionally grow side by side in the same patch of skin, and share ultraviolet radiation as a common trigger.
Why One Cannot Become the Other
The reason squamous cell carcinoma (SCC) cannot morph into melanoma comes down to cellular identity. Melanocytes originate from neural crest cells during embryonic development, migrating into the skin’s basal layer where they produce melanin pigment.1PubMed Central. Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma Keratinocytes, the cells behind SCC, come from a completely different embryonic lineage. Each cancer retains the molecular fingerprint of its parent cell. A squamous cell carcinoma carries keratinocyte markers and lacks melanocyte markers; a melanoma does the opposite. When a pathologist examines a biopsy under the microscope and runs immunohistochemical stains, these markers reliably distinguish one from the other. A tumor that tests positive for S100 and other melanocyte markers is melanoma; one that expresses keratin markers is SCC.
Cancer cells can behave unpredictably, but “turning into” a fundamentally different cancer type is not part of their repertoire in any clinically observed scenario involving SCC and melanoma. When researchers talk about “lineage plasticity” in cancer, they mean a tumor cell can shift its behavior within a range, not that it jumps wholesale from one cell lineage to an unrelated one.
What Lineage Plasticity Actually Means
The concept of lineage plasticity has gotten attention in cancer research, and it occasionally fuels confusion about whether one cancer type can become another. Melanoma itself is known to display phenotypic plasticity, meaning melanoma cells can take on characteristics of other cell types like blood vessel or nerve cells during their growth.2PubMed Central. Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance This plasticity helps melanoma cells invade tissue, resist therapy, and spread. Some melanoma cells under treatment pressure can adapt by switching phenotypes, including changes to their metabolic activity and invasive behavior, which contributes to drug resistance.3PubMed Central. Phenotype Switching in Melanoma: Implications for Progression and Therapy
Similarly, basal cell carcinoma (BCC) cells treated with targeted therapy have been observed assuming alternate cellular identities to survive when their original growth pathway is blocked.4PubMed Central. Lineage Plasticity in Cancer: The Tale of a Skin-Walker But all of this plasticity occurs within a single tumor’s own lineage or into closely related cell states. It does not involve an SCC becoming a melanoma or vice versa. The distinction matters because plasticity is about a cancer cell’s flexibility in behavior, not a wholesale identity swap between two unrelated tumor types.
A Curiosity from the Lab
One laboratory experiment has shown that it is technically possible to push keratinocyte-derived cells toward melanocyte-like characteristics in a dish. Researchers took keratinocyte cell lines, including one derived from a metastatic SCC, and used specific culture conditions to coax them into expressing melanocyte markers like MITF, DCT, and tyrosinase, while their original keratinocyte markers were downregulated. Interestingly, these transdifferentiated cells actually lost their ability to form tumors.5Nature. Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage The experiment demonstrated that while forced lineage switching is possible under artificial conditions, the result was less dangerous rather than more. The transdifferentiated cells behaved more like normal melanocytes than like melanoma.
This finding is relevant for basic science but has no clinical implications for patients. Nobody’s SCC is spontaneously undergoing this process in their body. The controlled laboratory environment required to achieve this conversion does not exist inside living skin. If anything, the experiment reinforces the idea that the two lineages are deeply distinct and that crossing from one to the other strips away the malignant characteristics rather than creating a new type of cancer.
When SCC Looks Like Melanoma
One practical reason people wonder about a connection between the two cancers is that some squamous cell carcinomas can look strikingly similar to melanoma on the skin’s surface. Pigmented SCC is a rare variant that accumulates enough melanin to appear dark brown or black, mimicking the appearance of melanoma to the naked eye. This variant is more common in people with darker skin tones, and it can also resemble pigmented basal cell carcinoma or seborrheic keratosis.6PubMed Central. Pigmented squamous cell carcinoma in situ with amyloid deposition mimicking melanoma A pigmented SCC in situ on a finger or other sun-exposed area can clinically mimic melanoma closely enough that even experienced dermatologists may need a biopsy to tell them apart.7Journal of Skin. Digital Pigmented Squamous Cell Carcinoma In-situ: A Case Report
The confusion also runs in the other direction. Spindle cell melanoma, a variant where melanoma cells take on an elongated shape, can look very similar to spindle cell SCC under the microscope. Both tend to arise on chronically sun-damaged skin, often on the head and neck of older adults. Pathologists use specialized staining to tell them apart. One study found that the p75 nerve growth factor receptor stained positive in all tested spindle cell melanomas but only about one in five spindle cell SCCs, making it a useful distinguishing marker alongside S100 protein.8The American Journal of Dermatopathology. P75 Nerve Growth Factor Receptor as a Useful Marker to Distinguish Spindle Cell Melanoma From Other Spindle Cell Neoplasms of Sun-Damaged Skin The takeaway for patients is straightforward: if your doctor is uncertain whether a dark lesion is SCC or melanoma, a biopsy and proper staining will resolve it. The clinical look-alike problem is a diagnostic challenge, not evidence that one cancer is becoming the other.
Collision Tumors and Combined Tumors
There is a genuinely unusual situation where SCC and melanoma occupy the same physical space, but even here, one is not transforming into the other. These are called collision tumors: two independent cancers that happen to develop at the same anatomical site and grow into each other. A case report described a scalp nodule removed from a 70-year-old man that contained nests of melanoma cells surrounded by squamous carcinoma cells, confirmed by dual immunohistochemical staining.9PubMed. Symbiotic collision tumour of the scalp: squamous cell carcinoma and malignant melanoma Another case described a collision tumor with invasive SCC and an ulcerated melanoma with a Breslow thickness of 9 mm growing together in a single nodule.10Journal of Plastic, Reconstructive & Aesthetic Surgery. A collision tumour of squamous cell carcinoma and malignant melanoma
A literature review and case report examined an even rarer entity: a tumor on the chest of an 84-year-old man that contained both squamous and melanocytic malignant components in a combined pattern, raising the question of whether the tumor was truly combined (arising from a shared precursor) or a collision (two independent tumors merging).11The American Journal of Dermatopathology. Malignant Melanoma Within Squamous Cell Carcinoma and Basal Cell Carcinoma: Is it a Combined or Collision Tumor?—A Case Report and Review of the Literature The debate over combined versus collision tumors is mostly academic; in either case, each component retains its own cell identity and is treated according to its own type. The SCC component is managed as SCC, and the melanoma component is managed as melanoma.
These cases are extremely rare. They appear in the literature as individual case reports, which tells you something about their frequency. But they do explain why a patient who had what looked like a single skin growth might hear both “squamous cell carcinoma” and “melanoma” mentioned in their pathology results.
A Rare Diagnostic Middle Ground
Adding one more layer of complexity, pathologists have described a handful of unusual growths called dermal squamo-melanocytic tumors. These are lesions that contain features of both squamous and melanocytic cells but do not fit cleanly into either category. Four cases were reported in middle-aged and older adults, all developing on the face as small purple-black nodules. After complete surgical removal, none of the tumors recurred or spread over a follow-up period averaging just over three years.12PubMed Central. Dermal squamo-melanocytic tumor: a unique biphenotypic neoplasm of uncertain biological potential The fact that they are classified as having “uncertain biological potential” reflects genuine uncertainty about what these growths are and how they behave, but they remain a pathological curiosity rather than evidence that one common skin cancer transforms into another.
Why Both Cancers Show Up in the Same Patients
A person who has had SCC has a higher-than-average likelihood of developing melanoma at some point, and vice versa. This is not because one causes the other. It is because both cancers share the same major risk factor: cumulative ultraviolet radiation damage to the skin. The field cancerization concept, proposed over 60 years ago and now confirmed by genetic sequencing, explains how UV radiation creates broad zones of damaged skin where multiple precancerous and cancerous growths can develop simultaneously.13PubMed Central. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas Within a field of sun-damaged skin, the earliest clonal proliferations have been identified, and they can give rise to multiple independent cancers. These might include SCC, actinic keratoses, basal cell carcinoma, and melanoma, all developing from their respective cell types in the same sun-battered patch of skin.
This shared exposure history means that if you have been diagnosed with one skin cancer, your dermatologist will monitor you for all types going forward. A new dark spot appearing near a previously treated SCC is not the old cancer changing form; it is more likely a second independent cancer arising from the same damaged skin field. The practical response is the same either way: get it biopsied and properly identified.
How the Two Cancers Differ in Behavior
Beyond their different cell origins, SCC and melanoma behave differently in ways that matter for treatment and prognosis. Most SCCs are slow-growing, stay local, and are cured by surgical removal. The overall risk of an SCC spreading to lymph nodes or distant organs is low, though certain high-risk features (large size, deep invasion, location on the lip or ear, involvement of nerves) raise that risk. Melanoma, by contrast, is far more likely to metastasize, and its prognosis depends heavily on how thick the tumor is when first diagnosed and whether it has already spread.
The treatment approaches diverge accordingly. SCC treatment typically involves surgical excision or Mohs surgery, with radiation or systemic therapy reserved for advanced cases. Melanoma treatment may involve wide local excision, sentinel lymph node biopsy, immunotherapy, or targeted therapy depending on the stage. Immunotherapy drugs that block PD-1 have been used across several cancer types including melanoma and head and neck squamous cell carcinoma, with researchers finding that immune-related gene signatures in the tumor could help predict response to treatment.14AACR Journals (Cancer Research). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma The overlap in immunotherapy use is another area where people may understandably wonder if these cancers are related, but shared responsiveness to a class of drugs does not mean the cancers are biologically interchangeable.
The Emotional Weight of a Skin Cancer Diagnosis
Part of what drives the question “can my SCC become melanoma?” is fear. Melanoma carries a more alarming reputation than SCC, and patients diagnosed with SCC sometimes worry that their condition could escalate into something more dangerous. A qualitative study comparing the emotional experiences of patients diagnosed with melanoma versus SCC found that both groups experienced significant anxiety and life disruption after diagnosis, though the specific concerns and coping strategies differed between the two groups.15PubMed Central. Patients’ Emotional Experiences and Life Changes Following a Diagnosis of Skin Cancer: A Qualitative Study Comparing Melanoma and Squamous Cell Carcinoma
If you have been told you have SCC and are worried about melanoma, the honest reassurance is this: your SCC will not transform into melanoma. They are biologically separate diseases. What your SCC diagnosis does tell you is that your skin has sustained significant UV damage, which means you should take regular full-body skin checks seriously. Your dermatologist is already looking for melanoma every time they examine you, not because your SCC might change, but because the same sun exposure that caused the SCC also raises your risk of developing melanoma independently. Catching any new cancer early, whatever its type, is the most effective thing you can do.
When to Push for Answers
If you receive a pathology report that mentions both squamous and melanocytic features, or if a growth that was initially thought to be one type turns out to be the other after further testing, that does not mean a transformation occurred. It means the initial clinical impression was revised. Skin lesions can fool even experienced clinicians at the surface level, and the diagnostic tools exist specifically to resolve these ambiguities. A few situations where it is reasonable to ask your doctor for more detail:
- A dark or pigmented SCC: these are uncommon, and the dark color warrants confirmation via biopsy that melanoma has been ruled out.
- A collision tumor diagnosis: ask how each component will be treated and whether additional staging is needed for the melanoma portion.
- Multiple skin cancers of different types: discuss a surveillance schedule and whether field-directed treatments for sun-damaged skin might be appropriate.
- Pathology that mentions unusual or mixed features: consider requesting a second opinion from a dermatopathologist who specializes in complex or ambiguous skin tumors.
Dermatopathology has sophisticated tools for distinguishing these cancers, and the diagnostic confusion that exists at the clinical level largely dissolves once tissue is examined under the microscope with proper staining. The cases where ambiguity persists are rare enough to appear in the literature as individual reports, which is itself a measure of how unusual they are.